Competition in the Pharmaceutical Industry: The Case of PAH Drugs

Kevin Green

International Journal of the Economics of Business, 2009, vol. 16, issue 1, 55-71

Abstract: The nature and extent of competition between different therapies for a given medical condition often is an important and controversial issue in both antitrust cases and general strategic analysis in the pharmaceutical industry. The market for pulmonary arterial hypertension ('PAH') therapies provides an interesting case study for analyzing these issues. An event study analyzing how the stock prices of PAH therapy providers respond to competitive developments in the industry sheds light on the nature of competition among different types of therapies. The results support the view that the strength of competition between any two drugs for the same condition can vary greatly depending on factors such as the stage of the patient's disease, the mode of drug delivery, the mechanism of action, convenience/ease of use and other characteristics.

Keywords: Pharmaceutical Industry; Relevant Markets; Antitrust; Mergers (search for similar items in EconPapers)
Date: 2009
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.tandfonline.com/10.1080/13571510802638932 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:ijecbs:v:16:y:2009:i:1:p:55-71

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/CIJB20

DOI: 10.1080/13571510802638932

Access Statistics for this article

International Journal of the Economics of Business is currently edited by Eleanor Morgan

More articles in International Journal of the Economics of Business from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().